Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 2Plasma cell 1

Conditions

Multiple Myeloma 130Neoplasms, Plasma Cell 16Recurrence 14Lymphoma 10Neoplasms 9Immunoglobulin Light-chain Amyloidosis 8Monoclonal Gammopathy of Undetermined Significance 5Leukemia, Plasma Cell 5Hematologic Neoplasms 5Waldenstrom Macroglobulinemia 3Smoldering Multiple Myeloma 3Paraproteinemias 3Leukemia 3Respiratory Aspiration 2Ovarian Neoplasms 2Leukemia, Lymphocytic, Chronic, B-Cell 2Kidney Neoplasms 2Hypoventilation 2Gastrointestinal Neoplasms 2Disease 2Colorectal Neoplasms 2Colonic Neoplasms 2Breast Neoplasms 2Amyloidosis 2Venous Thromboembolism 1Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Thyroid Cancer, Papillary 1Taste Disorders 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Plasmablastic Lymphoma × Plasma cell × Clear all
NCT07113496 2025-08-13

RN1201injection for Relapsed/Refractory CD19+/BCMA+ Hematologic Malignancies

The First Affiliated Hospital with Nanjing Medical University

Phase 1 Not yet recruiting
27 enrolled
LymphoidPlasma cell

Plasmablastic Lymphoma, Burkitt Lymphoma, Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡